HUP0301244A2 - Rapamicinvegyület alkalmazása szív-és érrendszeri megbetegedések kezelésére szánt gyógyászati készítmény előállítására - Google Patents

Rapamicinvegyület alkalmazása szív-és érrendszeri megbetegedések kezelésére szánt gyógyászati készítmény előállítására

Info

Publication number
HUP0301244A2
HUP0301244A2 HU0301244A HUP0301244A HUP0301244A2 HU P0301244 A2 HUP0301244 A2 HU P0301244A2 HU 0301244 A HU0301244 A HU 0301244A HU P0301244 A HUP0301244 A HU P0301244A HU P0301244 A2 HUP0301244 A2 HU P0301244A2
Authority
HU
Hungary
Prior art keywords
rapamycin
preparation
pharmaceutical composition
cardiovascular diseases
subject
Prior art date
Application number
HU0301244A
Other languages
English (en)
Inventor
Steven Jay Adelman
Neal Ivan Azrolan
Surendra Nath Sehgal
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22789625&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0301244(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth filed Critical Wyeth
Publication of HUP0301244A2 publication Critical patent/HUP0301244A2/hu
Publication of HUP0301244A3 publication Critical patent/HUP0301244A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgya rapamicinvegyület alkalmazása emlősökben szív- ésérrendszeri, agyérrendszeri vagy periferiális érrendszeri megbetegedéskezelésére vagy meggátolására szánt gyógyászati készítményelőállítására. A talámány tárgya továbbá kombinációs készítmény, amelyrapamicinvegyületet és egy vagy több szert tartalmaz az alábbiakközül: ACE-inhibitorok, angiotenzin II receptor antagonisták,fibrinsav-származékok, HMG Co-A reduktáz inhibitorok, béta-adrenergblokkoló szerek, kalciumcsatorna blokkolók, antioxidánsok;antikoagulánsok vagy ösztrogént tartalmazó, hormonpótló terápiábanhasznos szerek. Ó
HU0301244A 2000-06-16 2001-06-14 Use of rapamycin for preparation of pharmaceutical composition to treat heart and cardiovascular diseases HUP0301244A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21211700P 2000-06-16 2000-06-16
PCT/US2001/019179 WO2001097809A2 (en) 2000-06-16 2001-06-14 Method of treating cardiovascular disease using rapamycin

Publications (2)

Publication Number Publication Date
HUP0301244A2 true HUP0301244A2 (hu) 2003-08-28
HUP0301244A3 HUP0301244A3 (en) 2005-01-28

Family

ID=22789625

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301244A HUP0301244A3 (en) 2000-06-16 2001-06-14 Use of rapamycin for preparation of pharmaceutical composition to treat heart and cardiovascular diseases

Country Status (19)

Country Link
US (1) US20020013335A1 (hu)
EP (1) EP1292302A2 (hu)
JP (1) JP2003535899A (hu)
KR (1) KR20030010710A (hu)
CN (1) CN1436076A (hu)
AR (1) AR028959A1 (hu)
AU (2) AU2001268446B2 (hu)
BR (1) BR0111601A (hu)
CA (1) CA2412636A1 (hu)
CZ (1) CZ20024115A3 (hu)
EA (1) EA200300027A1 (hu)
HU (1) HUP0301244A3 (hu)
IL (1) IL153405A0 (hu)
MX (1) MXPA02012410A (hu)
NO (1) NO20026008D0 (hu)
NZ (1) NZ523114A (hu)
PL (1) PL365455A1 (hu)
WO (1) WO2001097809A2 (hu)
ZA (1) ZA200300418B (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2269603E (pt) * 2001-02-19 2015-09-09 Novartis Ag Tratamento de tumores da mama com um derivado de rapamicina em combinação com exemestano
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
US20030220297A1 (en) 2002-02-01 2003-11-27 Berstein David L. Phosphorus-containing compounds and uses thereof
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
BR0313024A (pt) 2002-07-30 2005-07-12 Wyeth Corp Formulações parenterais contendo um hidroxiéster de rapamicina
CN100415233C (zh) * 2002-09-17 2008-09-03 惠氏公司 口服制剂
AU2003293529A1 (en) 2002-12-16 2004-07-29 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
AR042938A1 (es) 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
US7728033B2 (en) 2003-05-05 2010-06-01 Clinigene International Private Limited Mycophenolate mofetil in diabetic nephropathy
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
DE102004019845A1 (de) * 2004-03-29 2005-10-20 Krka Tovarna Zdravil D D Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung
US20050232965A1 (en) * 2004-04-15 2005-10-20 Robert Falotico Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque
PL1750862T3 (pl) * 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
CN100435755C (zh) * 2004-07-27 2008-11-26 微创医疗器械(上海)有限公司 药物洗脱支架
EP1656941A1 (en) * 2004-11-09 2006-05-17 Clinigene International Private Limited Compositions for the treatment of diabetic nephropathy
GB0503936D0 (en) 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
CN100384416C (zh) * 2006-03-20 2008-04-30 杨军 一种用于治疗心血管疾病的药物组合物
US20080175887A1 (en) * 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2011115695A1 (en) 2010-03-15 2011-09-22 Exxonmobil Chemical Patents Inc. Processes for the production of alcohols
EP2906214A1 (en) * 2012-10-12 2015-08-19 The Board of Regents of The University of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
US10098871B2 (en) * 2013-03-15 2018-10-16 Leslie B. Gordon Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
EP3089737B1 (en) 2013-12-31 2021-11-03 Rapamycin Holdings, LLC Oral rapamycin nanoparticle preparations and use
CN105997940A (zh) * 2016-05-11 2016-10-12 中国人民解放军第三军医大学 炎症微环境响应性纳米药物、其制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
PT994697E (pt) * 1997-06-13 2005-02-28 Wyeth Corp Formulacoes de rapamicina para administracao oral
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin

Also Published As

Publication number Publication date
JP2003535899A (ja) 2003-12-02
WO2001097809A2 (en) 2001-12-27
CA2412636A1 (en) 2001-12-27
ZA200300418B (en) 2004-04-15
US20020013335A1 (en) 2002-01-31
PL365455A1 (en) 2005-01-10
EA200300027A1 (ru) 2003-06-26
NZ523114A (en) 2004-07-30
CZ20024115A3 (cs) 2003-06-18
IL153405A0 (en) 2003-07-06
MXPA02012410A (es) 2003-04-25
NO20026008L (no) 2002-12-13
AU6844601A (en) 2002-01-02
AU2001268446B2 (en) 2005-08-11
BR0111601A (pt) 2003-07-01
KR20030010710A (ko) 2003-02-05
NO20026008D0 (no) 2002-12-13
AR028959A1 (es) 2003-05-28
EP1292302A2 (en) 2003-03-19
HUP0301244A3 (en) 2005-01-28
CN1436076A (zh) 2003-08-13
WO2001097809A3 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
HUP0301244A2 (hu) Rapamicinvegyület alkalmazása szív-és érrendszeri megbetegedések kezelésére szánt gyógyászati készítmény előállítására
CY1118206T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει καλσιποτριολη και βηταμεθαζονη
UA88270C2 (ru) Фармацевтический препарат и его применение для профилактики удара, диабета
HUP0400475A2 (hu) Egy AT1 receptor antagonista vagy egy ACE inhibitor vagy egy HMG-CO-A reduktáz inhibitor közül legalább két vegyület kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk
EA200501496A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
AU8206401A (en) Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
IL149496A (en) Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract
RU2006135205A (ru) Применение антагонистов рецептора ангиотензина ii для лечения острого инфаркта миокарда
MXPA04011835A (es) Tratamiento de combinacion para la depresion y ansiedad.
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
AU2006252210A1 (en) New association of a sinus node lf current inhibitor and an angiotensin-converting enzyme inhibitor, and pharmaceutical compositions containing it
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
MXPA02003484A (es) Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba.
MXPA05008843A (es) Sistema terapeutico que comprende amoxicilina y acido clavulanico.
MXPA04008460A (es) Composiciones farmaceuticas de un inhibidor de pde4 o pde3/4 y un antagonista de receptor de histamina.
GEP201606538B (en) Preoperative treatment of post operative pain
HUP0303910A2 (hu) Húgyhólyagbetegségek kezelésére szolgáló kappa-opiát agonisták alkalmazása gyógyszerkészítmények előállítására
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
EA200400691A1 (ru) Получение чистых стереоизомеров трицикло[5,2,1,02,6]дец-9-ил-ксантогената и содержащие их лекарственные средства
DE60120986D1 (de) Nicht-peptidische ccr1 rezeptor-antagonisten in kombination mit cyclosporin a zur behandlung von herztransplantatabstossung
EP1099446A3 (en) Combination treatment for depression and anxiety containing a CNS-penetrant NK-1 receptor antagonist and an antidepressant or anxiolytic agent
CA2426492A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
DE50208267D1 (de) Wirkstoff-kombination zur medikamentösen therapie der nikotinabhängigkeit
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань